中文摘要：

目的：检测三种癌-睾丸抗原NY—SAR-35、NY—TLU-57和NY—ESO-1基因mRNA在广西地区肝细胞癌（Hepatocellular carcinoma，HCC）中的表达，探讨其作为HCC特异性免疫治疗靶抗原的可能性。方法：利用逆转录-聚合酶链反应（RT-PCR）方法．检测NY-SAR-35、NY-TLU-57和NY—ESO-1基因在63例HCC组织、56例HCC癌旁组织和4例正常肝组织中的表达，随机选择4例RT-PCR阳性产物直接进行DNA序列测定，并将其表达结果与临床病理指标进行统计学分析。结果：所检测的三种基因在4例正常肝组织中无表达；在63例HCC组织中，NY—SAR-35表达率为38．1％（24／63），NY-TLU-57为4．8％（3／63），NY-ESO-1为23．8％（15／63）；在56例HCC癌旁组织中，NY—TLU-57和NY—ESO-1无表达，NY—SAR-35的表达率为26．8％（15／56）。基因表达与，临床病理指标关系的分析显示．这2-种癌-睾丸抗原的表达均与所分析的临床病理指标无关（P〉0．05）。结论：癌-睾丸抗原NY—SAR-35、NY—TLU-57和NY—ESO-1基因可特异性的表达于HCC中，其中NY—SAR-35、NY—ESO-1具有-定的表达频率，提示它们有可能作为HCC特异性免疫治疗的靶抗原。

英文摘要：

Objective： To detect the mRNA expression of three CTAs （NY-SAR-35, NY-TLU- 57 and NY-ESO-1） in hepatocellular carcinoma （HCC） and to investigate the possibility of applying the antigens as the target antigens for HCC specific immunotherapy. Methods： With reverse-transcription polymerase chain reaction （RT-PCR）, the expression of NY-SAR-35, NY-TLU-57 and NY-ESO-1 in 63 cases of HCC tissues, 56 cases of HCC paraneoplastic tissues and 4 cases of normal liver tissues was detected respectively. Four samples selected randomly from PCR positive products of each CT gene were directly sequenced. The results of expression and related clinicopathologic parameters were analyzed with SPSS 11.5 statistic analysis software. Results： None of the three genes can be detected in the normal liver tissues. Among 63 HCC tissues, NY-SAR-35, NY-ESO-1 and NY-TLU-5.7 mRNA were detected in 38.1%（24/63）, 23.8%（15/63）and 4.8%（3/63）, respectively. In the test of the 56 cases with HCC paraneoplastic tissues, neither NY-TLU-57 nor NY-ESO-1 mRNA can be detected, but 15 cases （15/56, 26.8%） can express NY-SAR-35 mRNA. No relationship was found between the expression of three CTAs genes and clinicopathological parameters （P〉0.05）. Conclusion： NY-SAR-35, NY- TLU-57 and NY-ESO-1 are expressed specifically in HCC. Moreover and NY-SAR-35 and NY-ESO-1 are expressed with relatively high frequency, so they are the potential targets for antigen-specific immunotherapy of HCC.